Vedolizumab (Entyvio)

Vedolizumab (Entyvio) is covered only for FDA‑approved adult (≥18) ulcerative colitis and Crohn’s disease, excludes off‑label uses and patients <18, and must be prescribed by or in consultation with a gastroenterologist. Initial approval (14 weeks) requires documented diagnosis and specified prior‑therapy trials (Crohn’s: a biologic OR a conventional systemic agent OR systemic corticosteroids OR corticosteroid contraindication; ulcerative colitis: trial of one systemic or biologic agent), dosing is 300 mg IV at weeks 0, 2, and 6 then every 8 weeks, and renewals (12 months) require documented therapeutic response.

"Ulcerative colitis (FDA-approved indication)"

Sign up to see full coverage criteria, indications, and limitations.